Articles Archives - Page 159 of 733

ThursdayAug 24, 2023 9:00 am

GolfLync Inc. Innovates Again by Creating the World’s First Virtual Golf Clubs(TM)

GolfLync, the innovative social media networking platform designed exclusively for golf enthusiasts, is ushering in a new era for the golfing community with its groundbreaking feature, Virtual Golf Clubs(TM) (“VGC”). This cutting-edge addition to the app empowers golfers to connect, share experiences, and create thriving golfing communities, making GolfLync the go-to destination for passionate golfers across the United States. The Evolution of Golfing Communities Golf has always been a sport that fosters camaraderie and social connections. Traditionally, golfers would come together at local golf courses and clubs, forming tight-knit communities based on their love for the game. With the rise…

WednesdayAug 23, 2023 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’

For the quarter ended June 30, 2023, RVLP reported net sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period; this strategy is designed to extend cash runway for future business development and changes in the company’s marketing mix The company’s marketing partner, Santen, has commenced the required registrational trial for UPNEEQ(R) in Japan and plans to begin the same in China in 2023 UPNEEQ(R) has strong U.S. intellectual property protection, with patents extending to 2039 RVL Pharmaceuticals launched its prescription ecommerce platform, Elevate, in July 2023, allowing providers…

WednesdayAug 23, 2023 9:00 am

Renovaro BioSciences Inc. (NASDAQ: RENB), Immunotherapy Biotech Company, Announces Intention to Unite With AI Tech Developer GEDi Cube, Seen as Major Multiplier Effect in the Fight Against Cancer

Combination of advanced AI machine learning technology and proven immunotherapy technology seen as “future of medicine” Demonstrated success that both companies have shown with their innovative developments is expected to expand synergistically Potential applications against variety of cancers The announcement of a binding and exclusive letter of intent to merge, between two of the most innovative companies in their respective fields, is seen as representing a potentially transformative step in the fight against cancer. Considering Renovaro BioSciences (NASDAQ: RENB), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy, that has already demonstrated significant results with its technology against pancreatic…

TuesdayAug 22, 2023 9:45 am

Electronic Servitor Publication Network Inc. (XESP) Committed to Improving Client Outcomes and Creating Shareholder Value

Through its “Growth as a Service” offering, XESP is making technology implementation easier and more effective Its Digital Engagement Engine(TM) allows it to achieve greater reach and lift, affording companies the ability to maintain control of their content while creating meaningful relationships with new customers and revenue streams This technology’s potential has seen XESP tap into growth in the conversational commerce market, offering meaningful conversations to end users through a combination of automation and cutting-edge data analysis, facilitating business growth and driving up engagement Electronic Servitor Publication Network (OTC: XESP), a market disruptor for B2B companies using advanced data analysis…

TuesdayAug 22, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Affirms Product Superiority in Its 2023 Human Oral Nicotine Study, NIC-H22-1

Lexaria’s NIC-H22-1 study proved that its patented DehydraTECH(TM)-nicotine tobacco-free pouch was statistically significantly faster-acting than alternatives The study, which involved 36 participants, embraced a randomized, double-blind, cross-over study design It also affirmed Lexaria's product superiority while also showing DehydraTECH’s potential Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released results from its 2023 human oral nicotine study NIC-H22-1. Of note was its patented DehydraTECH(TM)–nicotine tobacco-free pouch product superiority, particularly when pitted against world-leading brands ZYN(R) and on!(R). The study proved that Lexaria’s product was statistically significantly faster than the two alternatives in the median time…

MondayAug 21, 2023 11:15 am

Electronic Servitor Publication Network Inc. (XESP) Helping Companies Use Technology to Win Customers and Ensure End-to-End Customer Experiences

Electronic Servitor Publication Network is a technology-oriented digital engagement and activation company The company has developed and is commercializing its Digital Engagement Engine(TM), which helps companies elevate digital content and drive better digital interactions within current and new communities Customer experience experts agree that companies need to embrace technologies to maximize customer satisfaction and methodically cultivate superior end-to-end CX capabilities Using its sophisticated technology stack, employed as a managed service, XESP helps companies build end-to-end capabilities that allow them to win and maintain customers in the present, while capturing future opportunities Customer experience is the process of measuring, analyzing, enhancing,…

MondayAug 21, 2023 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Strategic Updates Concerning Patented DehydraTECH(TM) Technology

Lexaria's human oral nicotine study, NIC-H22-1, comparing world-leading brands and the company's DehydraTECH(TM)-Nicotine tobacco-free pouch, reported positive results, including higher pleasurable effects and reduced negative effects A new patent has been granted to Lexaria and is strategically important to the company's oral nicotine sector research and development efforts Lexaria continues to research diabetes control and weight loss with its DehydraTECH(TM)-CBD, announcing favorable animal study results and the intent to develop a human clinical study Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced updates regarding its patented DehydraTECH(TM) technology – which improves the way that…

MondayAug 21, 2023 9:45 am

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Among Companies Leading Charge to Abate Reliance on Chinese Tech Metals Amid Ongoing Trade War

The United States and other Western nations have been embroiled in trade tensions with China since 2018 as a consequence of China’s efforts to control its industries’ exports of metals critical to modern digital and green technologies China imposed new licensing controls on the exports of the metals gallium and germanium that it processes, prompting fresh concerns about China’s ability to choke resources to the global market it supplies Ucore Rare Metals is a supply chain innovator dedicated to increasing American production of critical metals in order to reduce reliance on trade with China Ucore’s proprietary RapidSX(TM) processing solution for…

MondayAug 21, 2023 9:00 am

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) Accelerating Crypto and Challenger Bank Market Growth

A report published by Allied Market Research noted that in 2019, the global challenger bank market generated $20.4 billion and should post over $471 billion in revenue by 2027 This growth will be attributed to the reduced associated costs, accessibility and overall convenience that the challenger bank market offers Through its strategic acquisition approach, FEXD is advancing this sector while offering consumers the services and flexibility they need By doing so, FEXD hopes to reduce poverty, improve the lives of the unbanked, and offer security and saving options for migrant workers Fintech Ecosystem Development (NASDAQ: FEXD) is, through strategic mergers…

FridayAug 18, 2023 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment

Similar business model but different antibody therapies for psoriasis treatment, BiondVax uses NanoAbs while Apogee Therapeutics, Inc. uses conventional mAbs BiondVax NanoAbs provide superior benefits not seen in mAb therapies, including new routes of administration, higher affinity, better binding, and a higher level of stability at room temperature Apogee recently went public at $500 million pre-money, raising $300 million in an upsized deal, and has a $1 billion market cap – should be an eye-opener to BiondVax investors who recognize benefits of NanoAbs over mAb development The global psoriasis treatment market was valued at $26.13 billion in 2022 and is…

Site Search

Company Search

Category: Articles